Cargando…

Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide, with fibrosis stage being the main predictor for clinical outcomes. Here, we present the metabolic profile of NAFLD patients with regards to fibrosis progression. We included all consecutive new referrals...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jambulingam, Nila, Forlano, Roberta, Preston, Benjamin, Mullish, Benjamin H., Portone, Greta, Baheer, Yama, Yee, Michael, Goldin, Robert D., Thursz, Mark R., Manousou, Pinelopi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961068/ https://www.ncbi.nlm.nih.gov/pubmed/36834973 http://dx.doi.org/10.3390/ijms24043563

Ejemplares similares

The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease
por: Forlano, Roberta, et al.
Publicado: (2022)

Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter?
por: Forlano, Roberta, et al.
Publicado: (2021)

Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review
por: Forlano, Roberta, et al.
Publicado: (2022)

High-Throughput, Machine Learning–Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease
por: Forlano, Roberta, et al.
Publicado: (2020)

Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
por: Huang, Jian, et al.
Publicado: (2023)

Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non‐alcoholic fatty liver disease; the importance of an elevated mean platelet volume
por: Abeles, Robin D., et al.
Publicado: (2019)

Screening for NAFLD—Current Knowledge and Challenges
por: Forlano, Roberta, et al.
Publicado: (2023)

Current and future pharmacological therapies for managing cirrhosis and its complications
por: Kockerling, David, et al.
Publicado: (2019)

Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts
por: Eng, Pei Chia, et al.
Publicado: (2023)

THU642 Progression To Cirrhosis And All-cause Mortality Are Increased In Postmenopausal Women With NAFLD
por: Izzi-Engbeaya, Chioma, et al.
Publicado: (2023)

In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19
por: Forlano, Roberta, et al.
Publicado: (2020)

The effects of dietary supplementation with inulin and inulin‐propionate ester on hepatic steatosis in adults with non‐alcoholic fatty liver disease
por: Chambers, Edward S., et al.
Publicado: (2018)

Effect of COVID-19 lockdown on alcohol consumption in patients with pre-existing alcohol use disorder
por: Kim, Jin Un, et al.
Publicado: (2020)

1171. Impact on Mortality, Length of Stay, and Antibiotic Use in Allogenic and Autologous Stem Cell Transplant Patients Colonized With Carbapenemase-Producing Enterobacteriaceae
por: Ghani, Rohma, et al.
Publicado: (2018)

Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study
por: Appleby, Richard N., et al.
Publicado: (2019)

Thrombin and factor Xa link the coagulation system with liver fibrosis
por: Dhar, Ameet, et al.
Publicado: (2018)

Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study
por: Hanley, Brian, et al.
Publicado: (2020)

The Role of Liver Fibrosis Assessment in the Management of Patients with Chronic Hepatitis B Infection: Lessons Learned from a Single Centre Experience
por: Malik, Raza, et al.
Publicado: (2011)

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Complements are involved in alcoholic fatty liver disease, hepatitis and fibrosis
por: Lin, Cheng-Jie, et al.
Publicado: (2018)

Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Ramai, Daryl, et al.
Publicado: (2021)

Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis
por: Ghandian, Sina, et al.
Publicado: (2022)

Severe cholestatic jaundice after a single administration of ajmaline; a case report and review of the literature
por: Mullish, Benjamin H, et al.
Publicado: (2014)

Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease
por: Cheah, Mark CC, et al.
Publicado: (2017)

Non-invasive fibrosis assessment in non-alcoholic fatty liver disease
por: Rios, Rafael S., et al.
Publicado: (2020)

Risk Predictors of Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Olteanu, Vasile-Andrei, et al.
Publicado: (2022)

Non-alcoholic Fatty Liver Disease and Liver Fibrosis during Aging
por: Li, Yuan, et al.
Publicado: (2022)

Multimodal assessment of non-alcoholic fatty liver disease with transmission-reflection optoacoustic ultrasound
por: Lafci, Berkan, et al.
Publicado: (2023)

IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis
por: Vergis, N., et al.
Publicado: (2021)

Two Metabolomics Phenotypes of Human Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease According to Fibrosis Severity
por: Buchard, Benjamin, et al.
Publicado: (2021)

Hepatic Unsaturated Fatty Acids Are Linked to Lower Degree of Fibrosis in Non-alcoholic Fatty Liver Disease
por: Fridén, Michael, et al.
Publicado: (2022)

Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease
por: Daher, Saleh, et al.
Publicado: (2018)

Biomarkers of Type IV Collagen Turnover Reflect Disease Activity in Patients with Early-Stage Non-Alcoholic Fatty Liver (NAFL)
por: Lønsmann, Ida, et al.
Publicado: (2023)

Reappraisal of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score for advanced fibrosis in average-risk population
por: Park, Huiyul, et al.
Publicado: (2022)

Cohorting inpatients with Omicron and Delta variants of Sars-CoV-2 does not increase rates of mixed infection
por: Davies, Jessica, et al.
Publicado: (2022)

Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease
por: Gallego-Durán, Rocío, et al.
Publicado: (2016)

Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients
por: Zelber-Sagi, Shira, et al.
Publicado: (2017)

Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease
por: Campos-Murguía, Alejandro, et al.
Publicado: (2020)

Psychological Biomarkers and Fibrosis: An Innovative Approach to Non-alcoholic Fatty Liver Disease
por: Funuyet-Salas, Jesús, et al.
Publicado: (2020)

Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease
por: Katsarou, Angeliki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_plq8oou84ferg4aobcoibp3qvk